Related Experiment Video
Updated: Apr 3, 2026
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations
Xavier Cahu1,2, Stefan N Constantinescu3,4
1Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 75-4, Brussels, B1200, Belgium.
Abstract:
During the past 10 years, major progress has been accomplished with the discovery of activating mutations that are associated with the vast majority of BCR-ABL negative human myeloproliferative neoplasms (MPNs). The identification in 2005 of JAK2 V617F triggered great interest in the JAK2-STAT5/STAT3 pathway. Discovery in 2006 of mutants of thrombopoietin receptor (TPO-R/MPL) and later on of mutants in negative regulators of JAK-STAT pathway led to the notion that persistent JAK2 activation is a hallmark of MPNs. In 2013, mutations in the gene coding for the chaperone calreticulin were reported in 20-30% of essential thrombocythemia and primary myelofibrosis patients. Here, we will address the question: what do we know about calreticulin that could help us understand its role in MPNs? In addition to oncogenic driver mutations, certain MPNs also exhibit epigenetic mutations. Targeting of both oncogenic drivers and epigenetic defects could be required for effective therapy.
Insights
Discoveries in myeloproliferative neoplasms (MPNs) include mutations in JAK2, thrombopoietin receptor, and calreticulin. Understanding calreticulin
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Significant advancements in understanding BCR-ABL negative myeloproliferative neoplasms (MPNs) over the past decade.
- Discovery of activating mutations, including JAK2 V617F, MPL, and calreticulin, has elucidated key pathways like JAK-STAT.
- Persistent JAK2 activation is recognized as a hallmark of MPNs.
Purpose of the Study:
- To review current knowledge regarding calreticulin and its potential role in MPNs.
- To explore the implications of calreticulin mutations in essential thrombocythemia and primary myelofibrosis.
- To discuss the interplay between oncogenic driver mutations and epigenetic defects in MPN pathogenesis.
Main Methods:
- Literature review of recent discoveries in MPN genetics.
- Analysis of the functional significance of calreticulin mutations.
- Discussion of therapeutic strategies targeting both genetic and epigenetic alterations.
Main Results:
- Calreticulin mutations are found in 20-30% of essential thrombocythemia and primary myelofibrosis patients.
- The JAK2-STAT signaling pathway is critically involved in MPN development.
- Epigenetic mutations coexist with oncogenic drivers in some MPNs.
Conclusions:
- Calreticulin mutations represent a significant finding in MPN research.
- A comprehensive understanding of calreticulin's function is crucial for MPN research.
- Combined targeting of oncogenic drivers and epigenetic defects may be necessary for effective MPN therapies.
Related Concept Videos
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
02:23Abnormal Proliferation
01:15Differentiation of Common Myeloid Progenitor Cells
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes